Abstract
Ischemic brain damage develops at a pace slower than previously believed. In the penumbral area of the ischemic territory after focal ischemia, or in selectively vulnerable regions following transient global ischemia, cell death occurs hours or days following the acute insult. The process is the result of a complex cascade of pathogenic events, in which local and systemic factors play a role. Early and late excitotoxicity, apoptosis and inflammation have been found to contribute to the maturation of the damage. Mechanisms include calcium overload, oxidative stress, mitochondrial dysfunction, as well as damage to DNA, structural proteins and enzymes. Ischemic brain injury can be counteracted, totally or in part, by appropriate therapeutic interventions, resulting in varying degrees of neuroprotection in animal models. Although clinical trials based on neuroprotective agents have been disappointing, therapeutic strategies targeting recently identified pathogenic processes offer new hope. These approaches, alone or in combination with therapies based on early reperfusion of the ischemic brain, are likely to provide powerful tools for the treatment of human stroke.
Keywords: brain ischemia, penumbra, maturation phenomenon, excitotoxicity, oxidative stress, inflammation, programmed cell death, neuroprotection
Current Neuropharmacology
Title: Pharmacological Neuroprotection in Stroke: Rationale, State-of-the-art and Future Directions
Volume: 2 Issue: 3
Author(s): Francesco Orzi, Giuliano Sette, Ping Zhou and Costantino Iadecola
Affiliation:
Keywords: brain ischemia, penumbra, maturation phenomenon, excitotoxicity, oxidative stress, inflammation, programmed cell death, neuroprotection
Abstract: Ischemic brain damage develops at a pace slower than previously believed. In the penumbral area of the ischemic territory after focal ischemia, or in selectively vulnerable regions following transient global ischemia, cell death occurs hours or days following the acute insult. The process is the result of a complex cascade of pathogenic events, in which local and systemic factors play a role. Early and late excitotoxicity, apoptosis and inflammation have been found to contribute to the maturation of the damage. Mechanisms include calcium overload, oxidative stress, mitochondrial dysfunction, as well as damage to DNA, structural proteins and enzymes. Ischemic brain injury can be counteracted, totally or in part, by appropriate therapeutic interventions, resulting in varying degrees of neuroprotection in animal models. Although clinical trials based on neuroprotective agents have been disappointing, therapeutic strategies targeting recently identified pathogenic processes offer new hope. These approaches, alone or in combination with therapies based on early reperfusion of the ischemic brain, are likely to provide powerful tools for the treatment of human stroke.
Export Options
About this article
Cite this article as:
Orzi Francesco, Sette Giuliano, Zhou Ping and Iadecola Costantino, Pharmacological Neuroprotection in Stroke: Rationale, State-of-the-art and Future Directions, Current Neuropharmacology 2004; 2 (3) . https://dx.doi.org/10.2174/1570159043359648
DOI https://dx.doi.org/10.2174/1570159043359648 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Axotomy Leads to Reduced Calcium Increase and Earlier Termination of CCL2 Release in Spinal Motoneurons with Upregulated Parvalbumin Followed by Decreased Neighboring Microglial Activation
CNS & Neurological Disorders - Drug Targets Huntingtons Disease: The Value of Transcranial Meganetic Stimulation
Current Medicinal Chemistry The Ultimate Outlier: Transitional Care for Persons with Dementia and BPSD
Current Alzheimer Research Advances of Liquid Chromatographic Determination of Fumonisins; Potential Mycotoxins for Humans
Current Pharmaceutical Analysis Mechanistic Considerations on the Development of Lung Edema: Vascular, Perivascular and Molecular Aspects from Early Stage to Tissue and Vascular Remodeling Stage
Current Respiratory Medicine Reviews Scenario of the Treatment of Arthritis with Natural Products
Recent Patents on Inflammation & Allergy Drug Discovery Neurophysiology and Treatment of Disorders of Consciousness Induced by Traumatic Brain Injury: Orexin Signaling as a Potential Therapeutic Target
Current Pharmaceutical Design Astrocytes: Implications for Neuroinflammatory Pathogenesis of Alzheimers Disease
Current Alzheimer Research TIMP-2 Polymorphisms Define Subtypes of Hypertensive Intracerebral Hemorrhage with Distinct Perihematomal Edema Development Patterns
Current Neurovascular Research Neurological Substrate of Central Auditory Processing Deficits in Children
Current Pediatric Reviews Aminochrome as New Preclinical Model to Find New Pharmacological Treatment that Stop the Development of Parkinson’s Disease
Current Medicinal Chemistry Homology-Based Design for Selective GSK-3 Peptide Inhibitors: Patent Applications and Type 2 Diabetes Mellitus
Current Signal Transduction Therapy Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology TRPV1 Channel: A Potential Drug Target for Treating Epilepsy
Current Neuropharmacology Therapeutic Effects of Rivastigmine and Alfa-Lipoic Acid Combination in the Charles Bonnet Syndrome: Electroencephalography Correlates
Current Clinical Pharmacology Therapeutics Targeting Nogo-A Hold Promise for Stroke Restoration
CNS & Neurological Disorders - Drug Targets A Potential Role for the Existence of Pericytes in the Neurovascular Unit of the Sexually Dimorphic Nucleus of the Rat Preoptic Area to Control Blood-Brain Barrier Function
Current Neurovascular Research Effects of Erythropoietin on Brain Function
Current Pharmaceutical Biotechnology Glycogen Synthase Kinase-3: A Potential Target for Drug Discovery in the Treatment of Neurodegenerative Disorders
Current Enzyme Inhibition Cerebrolysin and Aquaporin 4 Inhibition Improve Pathological and Motor Recovery after Ischemic Stroke
CNS & Neurological Disorders - Drug Targets